<DOC>
	<DOC>NCT01523860</DOC>
	<brief_summary>This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone in elderly patients with advanced stage Follicular Lymphoma.</brief_summary>
	<brief_title>Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histological proven diagnosis of Bcell CD20+ follicular NHL, grade I, II and IIIa of WHO Classification Untreated patients with the exception of prior limited radiotherapy Stage III or IV who require therapy according to SIE and GELF criteria Stage II with at least one of the following: Bulky disease (&gt;7 cm) LDH &gt;normal Systemic symptoms Beta2Microglobulin &gt;3 mg/l Extranodal involvement Active disease with rapid progression 5.Age from 65 to 80 years, geriatric score "FIT" (see Appendix B) 6.Life expectancy &gt;6 months 7.ECOG performance status 02 (see Appendix C) 8.LVEF ≥45% or FS ≥37% 9.ANC ≥1 x 109/l and Platelets count ≥75 x 109/l, unless due to bone marrow involvement by follicular lymphoma 10.Creatinine up to 1.5 x ULN 11.Conjugated bilirubin up to 2 x ULN 12.Alkaline phosphatase and transaminases up to 2 x ULN 13.Sending of bone marrow sample for Bcl2/IgH rearrangement evaluation 14.Written informed content Men not agreeing to take adequate contraceptive precautions during and for at least 6 months after cessation of therapy History of other malignancies within 3 years prior to study entry except for: adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage, localized prostate cancer treated surgically with curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with curative intent Medical condition requiring long term use (&gt;1 months) of systemic corticosteroids Active bacterial, viral, or fungal infection requiring systemic therapy 5. Concurrent medical condition which might exclude administration of therapy Cardiac insufficiency (NYHA grade III/IV; see Appendix D) Myocardial infarction within 6 months of entry on study Severe chronic obstructive pulmonary disease with hypoxemia Severe diabetes mellitus difficult to control with adequate insulin therapy Hypertension that is difficult to control Impaired renal function with creatinine clearance &lt;30 ml/min (see Appendix E) HIV positivity HBV positivity with the exception of patients HbsAg negative and Ab antiHbcore positive (these patients need to receive prophylaxis with Lamivudine) HCV positivity with the exception of patients with no laboratory signs of active chronic hepatitis and HCVRNA negativity CNS involvement by lymphoma 16. Participation at the same time in another study in which investigational drugs are used Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>